Table 3. Worldwide distribution of allele frequencies and their odds ratios for the three LOXL1 SNPs across all glaucoma phenotypes including the present cohort.
|
Type of glaucoma |
Phenotypes |
Population [n cases] |
rs1048661
(G) |
rs3825942
(G) |
rs2165241
(T) |
Reference |
||||||
|
Freq |
OR
(95% CI) |
p value |
Freq |
OR
(95%CI) |
p value |
Freq |
OR (95%CI) |
p value |
||||
| Primary |
POAG |
Iceland [n=90] |
0.711 |
1.32
(0.96–1.82) |
0.085 |
0.872 |
1.25
(0.81–1.91) |
0.32 |
0.55 |
1.36
(1.01–1.83) |
0.04 |
[9] |
| POAG |
Sweden [n=200] |
0.638 |
0.82
(0.61–1.10) |
0.19 |
0.863 |
0.87
(0.57–1.31) |
0.49 |
0.488 |
0.83
(0.63–1.09) |
0.18 |
[9] |
|
| POAG |
India [n=112] |
0.616 |
0.70
(0.40–1.24) |
0.112 |
0.83 |
1.53
(0.78–2.98) |
0.105 |
0.321 |
0.95
(0.54–1.67) |
0.426 |
[20] |
|
| PACG |
India [n=96] |
0.667 |
0.88
(0.49–1.59) |
0.332 |
0.755 |
0.94
(0.49–1.79) |
0.456 |
0.296 |
0.82
(0.45–1.50) |
0.262 |
[20] |
|
| POAG |
USA [n=331] |
0.724 |
1.02
(0.70–1.51) |
0.92 |
0.771 |
0.86
(0.57–1.30) |
0.54 |
0.412 |
0.83
(0.59–1.18) |
0.33 |
[12] |
|
| POAG |
Caucasians [n=279] |
NA |
NA |
NA |
0.829 |
NA |
0.583 |
0.424 |
NA |
0.056 |
[21] |
|
| POAG |
African-Americans [n=193] |
NA |
NA |
NA |
0.617 |
NA |
0.591 |
0.237 |
NA |
0.408 |
[21] |
|
| POAG |
Africans [n=170] |
NA |
NA |
NA |
0.622 |
NA |
0.217 |
0.226 |
NA |
0.472 |
[21] |
|
| Secondary | XFS |
Iceland [n=55] |
0.789 |
2.02
(1.32–3.09) |
1.3x10−3 |
0.982 |
10.1
(4.02–25.36) |
8.5x10−7 |
0.74 |
3.18
(2.12–4.76) |
1.9x10−8 |
[9] |
| XFG |
Iceland [n=75] |
0.827 |
2.56
(1.74–3.77) |
1.8x10−6 |
0.987 |
13.2
(5.59–31.29) |
4.1x10−9 |
0.753 |
3.40
(2.41–4.81) |
4.3x10−12 |
[9] |
|
| XFG |
Sweden [n=199] |
0.834 |
2.39
(1.72–3.34) |
2.7x10−7 |
0.995 |
27.3
(11.4–65.07) |
9.1x10−14 |
0.813 |
3.78
(2.77–5.14) |
3.1x10−17 |
[9] |
|
| XFS |
USA [n=72] |
0.819 |
3.03
(1.77–5.17) |
0.00003 |
0.986 |
9.68
(2.20–42.53) |
0.0003 |
NA |
NA |
NA |
[10] |
|
| XFG |
USA [n=50] |
0.787 |
1.86
(1.10–3.15) |
0.0222 |
0.939 |
3.05
(1.20–7.76) |
0.0194 |
0.667 |
2.30
(1.40–3.76) |
0.001 |
[11] |
|
| XFS/XFG |
USA [n=206] |
0.829 |
1.90
(1.23–2.93) |
0.005 |
0.988 |
20.9
(8.06–54.39) |
1.6x10−15 |
0.76 |
3.77
(2.56–5.55) |
1.2x10−11 |
[12] |
|
| XFS/XFG |
American and European [n=287] |
0.843 |
2.26
(1.71–2.99) |
7.74x10−9 |
0.959 |
5.97
(3.77–9.44) |
3.1x10−17 |
0.734 |
2.24
(1.76–2.86) |
4.8x10−24 |
[13] |
|
| XFS/XFG |
Germany and Italy [n=726] |
0.82 |
2.43
(2.00–2.97) |
2.9x10−19 |
0.965 |
4.87
(3.46–6.85) |
8.2x10−23 |
0.765 |
3.42
(2.85–4.11) |
1.9x10−40 |
[14] |
|
| XFG |
Europe [n=167] |
0.841 |
2.69
(1.59–4.54) |
9.91x10−19 |
0.994 |
37.29
(6.35–218.02) |
5.76x10−15 |
NA |
NA |
NA |
[18] |
|
| XFS/XFG |
India [n=50] |
0.72 |
1.49
(0.89–2.51) |
0.156 |
0.92 |
4.17
(1.89–9.18) |
0.0001 |
NA |
NA |
NA |
[15] |
|
| XFS/XFG |
Japan [n=59] |
0.008 |
1 |
NA |
NA |
NA |
[16] |
|||||
| XFS/XFG |
Japan [n=209] |
0.053 |
0.986 |
10.87
(4.59–27.25) |
1.30x10−11 |
0.017 |
[19] |
|||||
| XFS |
Australia [n=86] |
0.78 |
1.86
(1.27–2.76) |
8.5x10−4 |
0.95 |
3.81
(1.88–9.02) |
7.8x10−5 |
NA |
NA |
NA |
[17] |
|
| PG/PDS | USA [n=78] | 0.674 | 0.79 (0.49–1.25) | 0.309 | 0.852 | 1.24 (0.69–2.22) | 0.461 | 0.514 | 1.18 (0.77–1.81) | 0.432 | Present study | |